Qiagen is a diagnostics and research company with a strong Piotroski financial health score of 8 out of 9 and consistent earnings delivery, but thin 3% upside to analyst targets, a confirmed price downtrend, and an unfavorable reward-to-risk ratio of 0.58 suggest the current entry point offers insufficient margin of safety.
Thesis pillars
- Thin Upside Poor Asymmetry→Stable
- Strong Financial Health Score→Stable
- Consistent Earnings Delivery↑Improving
- +1 more pillar — see the Why tab for full reasoning
Qiagen N.V. (QGEN) Stock Analysis
Healthcare · Diagnostics & Research
Sell if holding. Analyst target reached at $41.81 — A.R:R is negative (-0.8) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Earnings in 7 days (event risk).
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing... Read more
Sell if holding. Analyst target reached at $41.81 — A.R:R is negative (-0.8) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Earnings in 7 days (event risk). Chart setup: No clear chart pattern; technical signals are mixed. Score 5.0/10, moderate confidence.
Passes 5/9 gates (clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and death cross (50MA < 200MA) and earnings proximity 7d<=7d. Suitability: moderate.
Recent developments
updated 2026-07-29Recent Developments — Qiagen N.V.
Latest news
- NEWS JPMorgan Chase & Co. Has Lowered Expectations for Qiagen (NYSE:QGEN) Stock Price - MarketBeat — MarketBeat negative
- NEWS Citigroup Lowers Qiagen (NYSE:QGEN) Price Target to $38.00 - MarketBeat — MarketBeat negative
- NEWS Qiagen Sets Date for Publication of 2025 Annual Financial Report - The Globe and Mail — The Globe and Mail neutral
- NEWS Qiagen (NYSE:QGEN) Sets New 12-Month Low - Should You Sell? - MarketBeat — MarketBeat negative
- NEWS Is Qiagen NV (QGEN) a Bargain After 10.7% Drop? GF Value Says Un - GuruFocus — GuruFocus negative
Generated 2026-07-31T00:14:35Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $41.81 — A.R:R is negative (-0.8) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Earnings in 7 days (event risk). Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $39.95. Score 5.0/10, moderate confidence.
Take-profit target: $43.15 (-8.3% upside). Prior stop was $39.95. Stop-loss: $39.95.
Analyst target reached - limited upside remaining; Earnings in 7 days (event risk); Weak overall score: 5.0/10.
Qiagen N.V. trades at a P/E of 21.6 (forward 16.1). TrendMatrix value score: 6.0/10. Verdict: Sell.
22 analysts cover QGEN with a consensus score of 3.7/5. Average price target: $44.
What does Qiagen N.V. do?Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide....
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.